Efficiency of metabolic screening in childhood cardiomyopathies

被引:26
作者
Bonnet, D
de Lonlay, P
Gautier, I
Rustin, P
Rotig, A
Kachaner, J
Acar, P
LeBidois, J
Munnich, A
Sidi, D
机构
[1] Hop Necker Enfants Malad, Serv Cardiol Pediat, F-75015 Paris, France
[2] Hop Necker Enfants Malad, Unite Rech Handicaps Genet Enfant, F-75015 Paris, France
[3] Hop Necker Enfants Malad, Dept Genet, F-75015 Paris, France
关键词
cardiomyopathy; metabolism; children; mitochondria;
D O I
10.1053/euhj.1997.0818
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim To estimate the efficiency of metabolic screening in children's cardiomyopathy. Methods and Results Blood glucose, lactate, pyruvate and ketone body, and carnitine levels were measured in 58 children referred with a cardiomyopathy of unknown origin. Organic acids, amino acids, oxidation of [1-C-14] fatty acids to CO2 and dehydrogenation of[9,10(-3)H] fatty acids by lymphocytes were measured. Mitochondrial respiratory chain complex activity was measured in skeletal muscle and in endomyocardial biopsies. Acid alpha-glucosidase activity was measured in infants with hypertrophic cardiomyopathy. The prevalence of metabolic disorders was 22.4% (13/58-CL95%: 11.4-33.3%): four infants had a storage disease (Pompe's disease (3), Hurler's disease (1); two patients had a fatty acid beta-oxidation defect (systemic carnitine deficiency (1) and very-long chain acyl-CoA dehydrogenase deficiency (1)); respiratory enzyme deficiency was diagnosed in seven patients. This defect was confined to the myocardium in six. In the remaining 45 patients, metabolic screening was unrevealing. Conclusion Metabolic screening should be performed in all children with cardiomyopathy as the prevalence of metabolic disorders is high in this population. This may help to define therapeutic strategy and to improve genetic counselling.
引用
收藏
页码:790 / 793
页数:4
相关论文
共 21 条
  • [1] AOYAMA T, 1995, AM J HUM GENET, V57, P273
  • [2] MITOCHONDRIAL MYOPATHIES
    DIMAURO, S
    BONILLA, E
    ZEVIANI, M
    NAKAGAWA, M
    DEVIVO, DC
    [J]. ANNALS OF NEUROLOGY, 1985, 17 (06) : 521 - 538
  • [3] FISHER A, 1991, MALADIES METABOLIQUE, P233
  • [4] CARDIOMYOPATHY WITH MITOCHONDRIAL-DNA MUTATIONS
    HATTORI, K
    OGAWA, T
    KONDO, T
    MOCHIZUKI, M
    TANAKA, M
    SUGIYAMA, S
    ITO, T
    SATAKE, T
    OZAWA, T
    [J]. AMERICAN HEART JOURNAL, 1991, 122 (03) : 866 - 869
  • [5] HERS HG, 1989, METABOLIC BASIS INHE, V1, P425
  • [6] KELLY DP, 1994, NEW ENGL J MED, V330, P913
  • [7] LEBIDOIS J, 1992, EUR J PEDIATR, V151, pS59, DOI 10.1007/BF02125805
  • [8] MARTINIUK F, 1990, AM J HUM GENET, V47, P73
  • [9] MOLECULAR LESION IN PATIENTS WITH MEDIUM-CHAIN ACYL-COA DEHYDROGENASE-DEFICIENCY
    MATSUBARA, Y
    NARISAWA, K
    MIYABAYASHI, S
    TADA, K
    COATES, PM
    [J]. LANCET, 1990, 335 (8705) : 1589 - 1589
  • [10] CLINICAL ASPECTS OF MITOCHONDRIAL DISORDERS
    MUNNICH, A
    RUSTIN, P
    ROTIG, A
    CHRETIEN, D
    BONNEFONT, JP
    NUTTIN, C
    CORMIER, V
    VASSAULT, A
    PARVY, P
    BARDET, J
    CHARPENTIER, C
    RABIER, D
    SAUDUBRAY, JM
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 1992, 15 (04) : 448 - 455